Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00242749 |
Condition | Intervention | Phase |
---|---|---|
Cancer of Head and Neck |
Drug: Gefitinib, Cisplatin and Radiotherapy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2 Trial to Evaluate ZD1839 (IRESSA) in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma (Unresectable &Inoperable) |
Estimated Enrollment: | 47 |
Study Start Date: | December 2002 |
Study Completion Date: | July 2007 |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Spain | |
Research Site | |
Málaga, Spain | |
Research Site | |
Badalona, Spain | |
Research Site | |
Santander, Spain | |
Research Site | |
Murcia, Spain |
Study Director: | AstraZeneca Spain Medical Director, MD | AstraZeneca |
Study ID Numbers: | 1839IL/0102 |
Study First Received: | October 20, 2005 |
Last Updated: | April 22, 2009 |
ClinicalTrials.gov Identifier: | NCT00242749 History of Changes |
Health Authority: | Spain: Spanish Agency of Medicines |
Head and Neck Cancer Disease Head Cancer Neck Cancer Cancer of Head Cancer of Neck |
Cancer of the Head Cancer of the Head and Neck Cancer of the Neck Neoplasms, Head and Neck |
Radiation-Sensitizing Agents Cisplatin Head and Neck Neoplasms Gefitinib Carcinoma |
Neoplasms Neoplasms by Site Radiation-Sensitizing Agents Cisplatin Antineoplastic Agents |
Therapeutic Uses Head and Neck Neoplasms Physiological Effects of Drugs Pharmacologic Actions |